What an FDA inspection report does not say
Reference page · published 2026-11-14
When FDA investigators finish inspecting a facility, they hand the owner a form before they leave. It is called a Form FDA 483, and it lists what they saw that they thought might break the law. FDA publishes some of these forms. People in this category read them the way they read a report card on a supplier.
They are worth reading. They are not a preview of the charges. FDA says so in writing: the form is not meant to be a complete list, and it is not a decision about whether anything is actually illegal. This page shows what the form is required to contain, what FDA says it is for, and one 2026 case where the single most serious accusation in the warning letter does not appear anywhere in the inspection report that came six months before it.
What the form is
FDA explains the form in its own frequently-asked-questions page. On when it is issued:
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Two words there do a lot of work: observed, and judgment. The form records what
a person saw and what that person thought about it. On what it is for, FDA is equally plain:
The FDA Form 483 notifies the company’s management of objectionable conditions.
Notifying a company is the job. Charging it is not.
The law requires the form to cover only two things
The form exists because a statute requires it. That statute is section 704(b) of the Food, Drug, and Cosmetic Act, which appears in the U.S. Code at 21 U.S.C. § 374(b). It is worth reading for how narrow it is:
Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, tobacco product, or cosmetic in such establishment (A) consists in whole or in part of any filthy, putrid, or decomposed substance, or (B) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.— 21 U.S.C. § 374(b)(1)
That is the whole requirement. Filth, or insanitary conditions. The statute says nothing about unapproved drugs, nothing about misbranding, and nothing about whether a product needs a license. In practice FDA's investigators write about much more than filth — the forms routinely cite manufacturing regulations and sometimes statutes. But the legal floor is a report about conditions, and that explains the shape of the document you are reading when you read one.
FDA's own answer to the question on this page
FDA's FAQ asks the question directly. Is the form meant to be a complete list of everything wrong at a firm?
Is the FDA Form 483 intended to be an all-inclusive list of every possible deviation from law and regulation?—No, it’s not.
The explanation that follows is the part worth keeping:
The FDA Form 483 is a report which does not include observations of questionable or unknown significance at the time of the inspection. There may be other objectionable conditions that exist at the firm that are not cited on the FDA Form 483. FDA investigators are instructed to note only what they saw during the course of the inspection.
And on what the form means for enforcement:
The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.
FDA then lists what it actually decides on. The form is one input of several:
The FDA Form 483 is considered, along with a written report called an Establishment Inspection Report, all evidence or documentation collected on-site, and any responses made by the company. The Agency considers all of this information and then determines what further action, if any, is appropriate to protect public health.
Note the second item on that list. The Establishment Inspection Report is the investigator's full narrative account, and it is not published alongside the form. So the document the public reads is, by FDA's own description, the shorter of the two documents FDA reads.
One case where the gap was measured
This index already covers a warning letter FDA sent to a Florida compounding facility, GenoGenix LLC, on January 20, 2026. That letter is the only one found in this index that charges a peptide on a second statutory track — as an unlicensed biological product, not simply as an unapproved drug. The compound was Thymosin Beta-4, and the reason the track applies is a question of size, which the 40-amino-acid line covers on its own page.
Here is the sequence, taken from the letter's own account of itself:
| Date | Event |
|---|---|
| February 4, 2025 | Firm registers with FDA as an outsourcing facility |
| July 14–18, 2025 | FDA investigators inspect the facility — five days |
| July 18, 2025 | Form FDA 483 issued |
| July 31, 2025 | Amended Form FDA 483 issued |
| Aug 29, Sep 30, Oct 31, Nov 30, 2025 | Four written responses from the firm |
| January 20, 2026 | Warning letter issued — 186 days after the 483 |
| March 3, 2026 | Warning letter posted publicly — 42 days after it was issued |
The letter describes its own basis plainly: FDA issued a Form FDA 483 to your facility on
July 18, 2025, and issued an amended Form FDA 483 on July 31, 2025.
It then lists the firm's
four responses, which it says it reviewed in detail
.
The inspection report runs 19 pages and carries 16 numbered observations. We counted the terms in it that the warning letter's biologic charge is built from, and compared them against the letter. Every one of them is in the letter and none is in the form:
| Term searched | Inspection report | Warning letter |
|---|---|---|
| biological product | 0 | 9 |
| biologics | 0 | 3 |
| license / licensed / licensure | 0 / 0 / 0 | 5 / 3 / 1 |
| Public Health Service | 0 | 1 |
| § 351 (of that Act) | 0 | 6 |
| 42 U.S.C. § 262 | 0 | 1 |
| biologics license application | 0 | 2 |
| unlicensed | 0 | 0 |
| biosimilar | 0 | 0 |
| § 503B | 6 | 38 |
The last two rows are why this is worth stating. The bottom pair of zero-zero rows is a control: it shows the count can come back empty on both sides, so an empty cell is a real absence and not a broken search. And the § 503B row is the one that matters most.
This inspection report does cite statute. Four of its sixteen observations cite the outsourcing-facility statute by subsection — Observation 13 cites § 503B(a)(10)(A), Observation 14 cites § 503B(a)(10)(B), Observation 15 cites § 503B, and Observation 16 cites § 503B(b)(2)(A). So the obvious explanation — that these forms never carry statutes at all, only the letters do — does not hold here. The investigators cited the law they needed and wrote nothing about biologics.
Which means the most serious legal theory in that letter was added somewhere between the amended form on July 31, 2025 and the letter on January 20, 2026, with no observation behind it. A firm reading its own inspection report in August 2025 — and responding to it four times — would have had no warning that the charge was coming.
How long the wait usually is
The gap is not unusual in length. Three cases in this index state both dates in their own documents:
| Firm | Form 483 issued | Warning letter issued | Gap |
|---|---|---|---|
| GenoGenix LLC | July 18, 2025 | January 20, 2026 | 186 days |
| Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine | October 29, 2020 | November 10, 2021 | 377 days |
| Tailor Made Compounding | October 24, 2018 | April 1, 2020 | 525 days |
Six months to a year and a half. During that window the published record shows an inspection happened and shows what was observed. It does not show what FDA concluded, because FDA has not concluded it yet.
The published signal that does carry a decision
There is a separate thing FDA publishes that does reflect a decision, and it is easy to miss. After an inspection, FDA assigns the facility a final classification. FDA defines the three possible values:
No Action Indicated (NAI) classification indicates a facility is in an acceptable state of compliance.
Voluntary Action Indicated (VAI) classification indicates the inspection found objectionable conditions or practices but the agency has determined the facility can voluntarily correct its deficiencies and will not recommend any action.
Official Action Indicated (OAI) classification indicates a facility is in an unacceptable state of compliance.
FDA says the classification letter is usually sent in a letter to the firm within 45 - 90
days from the close of an inspection, depending on the inspection type.
So the classification
is normally decided long before a warning letter appears, and it is the closer thing to a verdict.
A firm can be issued a 483 and still be classified VAI, which FDA describes as a case where it
will not recommend any action.
FDA attaches two warnings to that database, and both limit how far you can push it:
This database does not represent a comprehensive listing of all conducted inspections and should not be used as a source to compile official data.
Some inspection data may not be posted until a final enforcement action is taken. Descriptions of posted inspection citations may not necessarily represent citations on the final classification letters.
Read those together and an absence in that database means very little. A firm missing from it has not been cleared. It may simply not be posted yet — and FDA says outright that the posting may wait for the enforcement action to land.
What does the evidence not show?
It does not show that an inspection report is the weaker document. The clearest
counter-example in this index runs the other way. In the Tailor Made Compounding case, the warning
letter gave a single example of a product that missed its potency specification — a 200 mg
glutathione product, which the letter said was determined to have 88% the amount of glutathione
listed on the label.
The inspection report behind it is more
specific, not less. Its Observation 8 records that the firm released three products to patients
with out-of-specification potency results, and sets them out in a table with more than one test
result per lot. The letter named one product and introduced it with For example
. The form
named three and showed the readings.
And in that case the letter is the document that contradicts itself. It says
investigators found products in which the strength exceeded the label claim
, then gives a
figure of 88% of label, which is below it, then repeats that the strength differed from and
exceeded the labeled
amount. Eighty-eight per cent is not exceeding. The inspection report's
own table is the more coherent record. So the honest summary is not that the form is less reliable
than the letter — it is that they are different documents, and either one can
contain what the other leaves out.
It does not show a pattern, because one case is not a pattern. The GenoGenix comparison is a single letter and a single inspection report. It demonstrates that a charge can arrive with no inspectional footprint. It does not say how often that happens, and this index has not measured that.
It does not show what FDA was thinking. An absence in the form proves that the investigator did not write something down. It does not prove nobody at FDA had the idea. The agency says itself that it also weighs the Establishment Inspection Report, the collected evidence and the firm's responses — and we have not read any of those three for this case. The Establishment Inspection Report is not published with the form, and the firm's four responses are not public documents.
It does not show that the published forms can be read mechanically. Both inspection reports discussed on this page are scans of paper, not digital text. The text you can copy out of them is produced by character recognition and it is wrong in places: in the GenoGenix form the word methylcobalamin is rendered with the letters r and n in place of m, and a milligram-per-millilitre strength is rendered with a digit in place of a letter. A plain search of that text returns zero for a compound the document demonstrably names. Every count on this page was therefore re-measured with a search built to tolerate those substitutions, and checked first against a term known to be present to confirm the search worked. We also quote nothing from either form word-for-word, for the same reason — the statements attributed to the two inspection reports above are descriptions of their contents, while every passage in quotation marks on this page comes from a digital original.
It does not show that reading a 483 is pointless. It is the only public account of what an inspector actually saw in a facility. The argument of this page is narrower: read it as evidence of conditions on the days of the inspection, not as a forecast of what FDA will charge.
Where this sits in the record
If you are checking a supplier's federal record, the documents arrive in an order, and each one means something different. The inspection report is what an investigator saw. The warning letter is what the agency decided to allege. What follows a letter is a separate question again, and the honest answer there is mostly that the record goes quiet. The one thing that tends to be over-read in all of this is the subject line — the index column that describes a letter is written for filing, not for accuracy, and the GenoGenix letter is the proof: its subject line gives no hint that a biologic charge is inside it.
None of this is an accusation against any company. It is a note about how to read four kinds of federal document without assuming they say more than they do.
Sources
- US FDA — FDA Form 483 Frequently Asked Questions, content current as of 01/09/2020. fda.gov/…/fda-form-483-frequently-asked-questions — every quotation attributed to FDA's FAQ on this page is verbatim from this page as fetched on November 14, 2026.
- US Code — 21 U.S.C. § 374, Inspection (2023 edition), subsection (b)(1). govinfo.gov/…/USCODE-2023-title21…sec374.htm — the statutory requirement, quoted verbatim. This is section 704(b) of the Food, Drug, and Cosmetic Act.
- US FDA — Warning Letter, GenoGenix LLC, WL # 718739, January 20, 2026. fda.gov/…/genogenix-llc-718739-01202026 — the source of the dates, the four response dates and the counts in the letter column.
- US FDA — Form FDA 483, GenoGenix LLC, Boca Raton, FL, issued July 18, 2025, amended July 31, 2025 (19 pages, 16 observations). fda.gov/media/188559/download — a scan. Read for substance and for term counts; nothing is quoted from it word-for-word on this page.
- US FDA — Inspection Classification Database. fda.gov/…/inspection-classification-database — the source of the NAI, VAI and OAI definitions, the 45–90 day timing and the two limitations quoted above.
- US FDA — Warning Letter, Tailor Made Compounding LLC, Case # 594743, April 1, 2020. fda.gov/…/tailor-made-compounding-llc-594743-04012020 — the glutathione passage and the internal contradiction, quoted verbatim.
- US FDA — Form FDA 483, Tailor Made Compounding, LLC, Nicholasville, KY, issued October 24, 2018 (8 pages). fda.gov/media/134965/download — also a scan. Observation 8 and its table read for substance; not quoted word-for-word.
- US FDA — Warning Letter, Advanced Nutriceuticals, LLC dba The Guyer Institute of
Molecular Medicine, MARCS-CMS 615908, November 10, 2021.
fda.gov/…/advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021
— the source of both dates in that row. The letter states its own date and says
FDA issued a Form FDA 483 to your firm on October 29, 2020.
- Note on what the term counts mean. A count of zero in the inspection-report column means the term does not appear in the text recovered from that scan, searched with tolerance for the character-recognition errors described above. It is not a claim about what the investigators thought.
Further reading
- What an FDA warning letter is — the document that comes after the one on this page.
- After an FDA warning letter: the documented process.
- When FDA calls a peptide a biologic: the 40-amino-acid line — the charge that was missing from the inspection report.
- What the subject column in FDA's warning-letter index actually describes.
- The Tailor Made Compounding record.
- The Staska Pharmaceuticals record — a firm inspected again after its letter, with the inspection recorded as open.
- What FDA asks a manufacturer to prove.
- What a lot number proves — and what it does not.
- Is my peptide vendor compliant?
- About this index.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.